Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Lfb Biotechnologies

Centre Regional De Lutte Contre Le Cancer

Icm Institut Regional Du Cancer De Montpellier

Inserm (institut National De La Sante Et De La Recherche Medicale)

Institut Regional Du Cancer De Montpellier

Christine Gaucher

Christophe De Romeuf

Emmanuel Nony

Nicolas Bihoreau

Dominique Bourel

Isabelle Navarro-Teulon

Jean-François Prost

Christian Behrens

Arnaud Glacet

Sylvie Jorieux

Philippe Klein

Jean-luc Teillaud

Frédéric Dhainaut

Christophe Sirac

Arnaud Clacet

Jean-Luc Teillaud

Jean-Francois Prost

The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-M&#xfc;llerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.

Pharmaceutical compositions comprising an antibody which binds the human anti-M&#xfc;llerian hormone receptor type II

The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.

Use of ADCC-optimized antibodies for treating low-responder patients

The present invention relates to a monoclonal antibody method directed against CD20 antigen including administration of an anti CD20 antibody wherein each of the light chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 28, and each of the heavy chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 20.

Antibody method for treatment of a disease in which the target cells are cells which express CD20

Pharmaceutical compositions comprising an antibody which binds the human anti-mullerian hormone receptor type II

The invention is directed to a monoclonal antibody directed against CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19. The invention is further directed to methods of in vitro activation of Fc&#x3b3;RIIIA receptors in immune effector cells with the antibody and methods of treating CD20-expressing leukaemia or lymphoma with the antibody.

Monoclonal antibody directed against CD20 antigen

Use of ADCC-optimized antibodies for treating weak patients

The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4.

Anti-rhesus D monoclonal antibody

The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the Fc&#x3b3;RIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.

Cytotoxic antibodies directed against antibodies inhibiting factor VIII

The invention relates to a method of measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody, and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins, such as IFN? or IL2 which are intended for the treatment of autoimmune and inflammatory diseases, cancers and infections by pathogens.

Method of measuring activation of effector cells

Growing community of inventors

Sequedin, France

Christine Gaucher